Prospective, observational, multicenter study regarding the safety of Gammanorm in autoimmune diseases
Latest Information Update: 12 Mar 2021
At a glance
- Drugs Immune globulin (Primary)
- Indications Autoimmune disorders; Dermatomyositis; Inclusion body myositis; Multifocal motor neuropathy; Polymyositis; Polyneuropathy
- Focus Adverse reactions
- Acronyms Immunorm Study
- Sponsors Octapharma
- 09 Mar 2021 Status changed to discontinued.
- 01 Jan 2021 Status changed from active, no longer recruiting to completed.
- 03 Sep 2018 Status changed from recruiting to active, no longer recruiting.